OncoMatch/Clinical Trials/NCT04637763
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Is NCT04637763 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cyclophosphamide and Fludarabine for lymphoma, non-hodgkin.
Treatment: Cyclophosphamide · Fludarabine — CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
relapsed or refractory non-Hodgkin lymphoma after prior standard of care
Cannot have received: anti-CD19 therapy
Prior therapy with an anti-CD19 targeting agent
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplantation
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiac function
Adequate hematologic, renal, liver, cardiac and pulmonary organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- HonorHealth · Scottsdale, Arizona
- University of Arizona Cancer Center · Tucson, Arizona
- University of Arkansas · Little Rock, Arkansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify